01 December 2004
In vitro effect of neuropeptides on ovary or celiac ganglion affects the release of progesterone from ovaries in the rat.
Marisa Hilda Garraza, Luis Inocencio E Aguado, Miguel Angel De BortoliMed Sci Monit 2004; 10(12): BR440-446 :: ID: 13220
Abstract
BACKGROUND: The purpose of this work was to examine the in vitro effects of three neuropeptides--vasoactive intestinal peptide (VIP), neuropeptide Y (NPY), and substance P (SP)--on the release of ovarian progesterone (Po), acting directly on the ovary (O) or on the celiac ganglion (CG) of rats in diestrus 1 (D1) and 2 (D2), because in these two cycle stages neural effects have been observed on P release. MATERIAL/METHODS: Hemiovaries of rats in D1 and D2 were incubated with each neuropeptide alone and in combination with norepinephrine. Also, the CG-superior ovarian nerve (SON)-O system was incubated with the addition of each neuropeptide to the CG. RESULTS: In D1 ovaries, NPY, VIP or SP, both alone and with norepinephrine, generally decreased the release of Po. The effect of each neuropeptide was modified by norepinephrine. In D2, NPY, VIP or SP, both alone and with norepinephrine, increased Po release. The effect of NPY and SP was modified by norepinephrine. In the CG-SON-O system, in D1, the addition of NPY and VIP alone increased Po release, while SP decreased it. In D2, the three neuropeptides increased Po release. CONCLUSIONS: Of the studied situations, only the effects of NPY and VIP on the CG during D1 mirror the changes of progesterone in blood during the rat estrous cycle. These effects are in agreement with others obtained by intracerebroventricular injection of epinephrine, suggesting that these neuropeptides might be released on CG after this injection and produce increased progesterone in blood.
Keywords: Diestrus - drug effects, Ganglia, Sympathetic - drug effects, Ovary - innervation, Progesterone - analysis, Progesterone - biosynthesis, Substance P - pharmacology, Diestrus - drug effects, Ganglia, Sympathetic - drug effects, Neuropeptide Y - pharmacology, Neuropeptides - pharmacology, Ovary - metabolism, Progesterone - biosynthesis, Substance P - pharmacology, Vasoactive Intestinal Peptide - pharmacology
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952